DIAGNOSTIC UTILITY OF IMMUNOHISTOCHEMISTRY IN SUBTYPING ACUTE LYMPHOBLASTIC LEUKEMIA: A 2 YEARS’ EXPERIENCE

Main Article Content

Nazish Farooq
Muhammad Ihtesham Khan
Fazle Raziq
Shaleem Naeem

Abstract

OBJECTIVE: To determine the diagnostic importance of immunohistochemistry (IHC) in classifying acute lymphoblastic leukemia (ALL) in a tertiary care center.
METHODS: This cross-sectional descriptive study was done from January-2017 to December-2018 at Rehman Medical Institute, Peshawar, Pakistan. Out of 133 cases diagnosed as precursor lymphoid leukemia, two cases were excluded due to inadequacy of the aspirate smears and 131 cases were included in the study. The immune-phenotype was detected by IHC with immune-markers viz terminal deoxynucleotidyl transferase (TdT), CD34, CD10, CD79a, CD3, myeloperoxidase (MPO), CD117 and paired box protein 1 (PAX1).
RESULTS: Out of 131 cases included 99 (75%) were males and 32 (25%) were females. Mean age of the study participants was 20±16 years (range=16-65 years). Majority of the cases presented with hepatomegaly (n=113/131, 87%), followed by pallor (n=105/131, 80.1%), splenomegaly (n=89/131, 68%) and lymphadenopathy (n=82/131, 63%). Based on IHC, 114 (87.02%) cases were successfully classified to specific subtypes and 17 (13%) cases could not be assigned into any subtype. Eighty-six cases (65.7%) were of Pre-B cell ALL, 17 (13%) cases were T-cell ALL, 8 (6.1%) cases were Pre-T cell ALL while 3 (2.3%) cases were Pro-B lineage.
CONCLUSION: Study concludes that majority of the patients were male and presented with hepatomegaly and pallor. IHC is effective method to sub-classify ALL into various immune-phenotypes in low resource countries where flow cytometry is unavailable. Pre-B cell ALL is common than T-cell ALL.


KEY WORDS:  (MeSH);  (Non-MeSH);  (MeSH);  (MeSH),  (MeSH);  (MeSH);  (MeSH);  (MeSH)

Article Details

How to Cite
Farooq, N., Khan, M., Raziq, F., & Naeem, S. (2020). DIAGNOSTIC UTILITY OF IMMUNOHISTOCHEMISTRY IN SUBTYPING ACUTE LYMPHOBLASTIC LEUKEMIA: A 2 YEARS’ EXPERIENCE. KHYBER MEDICAL UNIVERSITY JOURNAL, 12(1), 38-42. https://doi.org/10.35845/kmuj.2020.19827
Section
Original Articles

References

1. Khan MI, Ahmad N, Fatima SH. Haematological disorders; analysis of hematological disorders through bone marrow biopsy examination. Professional Med J 2018; 25(6):828-34. DOI:10.29309/TPMJ/18.4500
2. Khan MI, Naseem L, Manzoor R, Yasmeen N. Mortality analysis in children during induction therapy for acute lymphoblastic leukemia. J Islamabad Med Dent Coll 2017; 6(2):69-72.
3. Pandian G, Sankarasubramaian ML. A study on clinical, immunophenotypic pattern in pediatric acute leukemias in a teaching hospital. Int J Contemp Pediatr 2018;5(4):1183-9. DOI: 10.18203/2349-3291.ijcp20182064.
4. Subashchandrabose P, Madanagopaal LR, Rao TMS. Diagnosis and classification of acute leukemia in bone marrow trephine biopsies, utility of a selected panel of minimal immunohistochemical markers. Int J Hematol Oncol Stem Cell Res 2016;10(3):138-46.
5. Khan MI. Acute myeloid leukemia: pattern of clinical and haematological parameters in a tertiary care centre. Int J Pathol 2018;16(2):58-63.
6: Chang F, Shamsi TS, Waryah AM. Clinical and hematological profile of acute myeloid leukemia (AML) patients of Sindh. J Hematol Thrombo Dis 2016;4(2):1000239. doi:10.4172/2329-8790.1000239.
7. Rathee R, Vashist M, Kumar A, Singh S. Incidence of acute and chronic forms of leukemia in Haryana. Int J Pharm Pharm Sci 2014;6:323-5.
8. Masood A , Masood K, Hussain M, Ali W, Riaz M, Alauddin Z et al. Thirty years cancer incidence data for Lahore, Pakistan: trends and patterns 1984-2014. Asian Pac J Cancer Prev 2018;19(3):709-17. DOI: 10.22034/APJCP.2018.19.3.709.
9. Gown AM. Diagnostic Immunohistochemistry: What Can Go Wrong and How to Prevent It. Arch Pathol Lab Med 2016;140(9):893-8. DOI: 10.5858/arpa.2016-0119-RA.
10. Coons AH, Creech HJ, Jones RN. Immunological properties of an antibody containing a fluorescent group. Exp Biol Med 1941;47:200-2. DOI: 10.3181/00379727-47-13084P.
11. Torlakovic EE, Nielsen S, Vyberg M, Taylor CR. Getting controls under control: the time is now for immunohistochemistry. J Clin Pathol 2015;68:879-82. DOI: 10.1136/jclinpath-2014-202705.
12. Bain BJ. Immunophenotyping and Cytogenetic/Molecular Genetic Analysis in Leukemia and Related Conditions. In: Leukemia diagnosis. 2010. pp. 64-113. 4th ed. Wiley–Blackwell, Singapore.
13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33(4):451-8. DOI: 10.1111/j.1365-2141.1976.tb03563.x.
14. Iwamoto S, Ohta H, Kiyokawa N, Fujimoto J, Tsurusawa M, Yamada T, et al. Flow Cytometric Analysis of de novo acute lymphoblastic leukemia in Childhood. Report from Japanese Pediatric Lymphoma/Leukemia study group. Int J Hematol 2011;94:185-92. DOI: 10.1007/s12185-011-0900-1.
15. Arber DA, Jenkins KA. Paraffin Section Immunophenotyping of Acute Leukemias in bone marrow specimens. Am J Clin Pathol 1996; 106: 462–68. DOI: 10.1093/ajcp/106.4.462.